Cargando…

Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers

Mephedrone is a stimulant drug structurally related to cathinone. At present, there are no data available on the excretion profile of mephedrone and its metabolites in urine after controlled intranasal administration to human volunteers. In this study, six healthy male volunteers nasally insufflated...

Descripción completa

Detalles Bibliográficos
Autores principales: Czerwinska, Joanna, Parkin, Mark C., George, Claire, Kicman, Andrew T., Dargan, Paul I., Abbate, Vincenzo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306721/
https://www.ncbi.nlm.nih.gov/pubmed/34984836
http://dx.doi.org/10.1002/dta.3214
_version_ 1784752604557869056
author Czerwinska, Joanna
Parkin, Mark C.
George, Claire
Kicman, Andrew T.
Dargan, Paul I.
Abbate, Vincenzo
author_facet Czerwinska, Joanna
Parkin, Mark C.
George, Claire
Kicman, Andrew T.
Dargan, Paul I.
Abbate, Vincenzo
author_sort Czerwinska, Joanna
collection PubMed
description Mephedrone is a stimulant drug structurally related to cathinone. At present, there are no data available on the excretion profile of mephedrone and its metabolites in urine after controlled intranasal administration to human volunteers. In this study, six healthy male volunteers nasally insufflated 100 mg of pure mephedrone hydrochloride (Day 1). Urine was collected at different timepoints on Day 1 and then on Days 2, 3 and 30. Samples were analysed for the presence of mephedrone and its metabolites, namely, dihydro‐mephedrone, nor‐mephedrone (NOR), hydroxytolyl‐mephedrone, 4‐carboxy‐mephedrone (4‐carboxy) and dihydro‐nor‐mephedrone (DHNM), by a validated liquid chromatography‐tandem mass spectrometry method. All analytes were detected in urine, where 4‐carboxy (C(max) = 29.8 μg/ml) was the most abundant metabolite followed by NOR (C(max) = 377 ng/ml). DHNM was found at the lowest concentrations (C(max) = 93.1 ng/ml). Analytes exhibited a wide range of detection windows, but only 4‐carboxy and DHNM were detectable in all samples on Day 3, extending the detection time of mephedrone use. Moreover, mephedrone had a mean renal clearance of 108 ± 140 ml/min, and 1.3 ± 1.7% of unchanged parent drug was recovered in urine in the first 6 h post administration. It is hoped that this novel information will be useful in future studies involving mephedrone and other stimulant drugs.
format Online
Article
Text
id pubmed-9306721
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-93067212022-07-28 Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers Czerwinska, Joanna Parkin, Mark C. George, Claire Kicman, Andrew T. Dargan, Paul I. Abbate, Vincenzo Drug Test Anal Short Communications Mephedrone is a stimulant drug structurally related to cathinone. At present, there are no data available on the excretion profile of mephedrone and its metabolites in urine after controlled intranasal administration to human volunteers. In this study, six healthy male volunteers nasally insufflated 100 mg of pure mephedrone hydrochloride (Day 1). Urine was collected at different timepoints on Day 1 and then on Days 2, 3 and 30. Samples were analysed for the presence of mephedrone and its metabolites, namely, dihydro‐mephedrone, nor‐mephedrone (NOR), hydroxytolyl‐mephedrone, 4‐carboxy‐mephedrone (4‐carboxy) and dihydro‐nor‐mephedrone (DHNM), by a validated liquid chromatography‐tandem mass spectrometry method. All analytes were detected in urine, where 4‐carboxy (C(max) = 29.8 μg/ml) was the most abundant metabolite followed by NOR (C(max) = 377 ng/ml). DHNM was found at the lowest concentrations (C(max) = 93.1 ng/ml). Analytes exhibited a wide range of detection windows, but only 4‐carboxy and DHNM were detectable in all samples on Day 3, extending the detection time of mephedrone use. Moreover, mephedrone had a mean renal clearance of 108 ± 140 ml/min, and 1.3 ± 1.7% of unchanged parent drug was recovered in urine in the first 6 h post administration. It is hoped that this novel information will be useful in future studies involving mephedrone and other stimulant drugs. John Wiley and Sons Inc. 2022-01-11 2022-04 /pmc/articles/PMC9306721/ /pubmed/34984836 http://dx.doi.org/10.1002/dta.3214 Text en © 2022 The Authors. Drug Testing and Analysis published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Short Communications
Czerwinska, Joanna
Parkin, Mark C.
George, Claire
Kicman, Andrew T.
Dargan, Paul I.
Abbate, Vincenzo
Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers
title Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers
title_full Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers
title_fullStr Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers
title_full_unstemmed Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers
title_short Excretion of mephedrone and its phase I metabolites in urine after a controlled intranasal administration to healthy human volunteers
title_sort excretion of mephedrone and its phase i metabolites in urine after a controlled intranasal administration to healthy human volunteers
topic Short Communications
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9306721/
https://www.ncbi.nlm.nih.gov/pubmed/34984836
http://dx.doi.org/10.1002/dta.3214
work_keys_str_mv AT czerwinskajoanna excretionofmephedroneanditsphaseimetabolitesinurineafteracontrolledintranasaladministrationtohealthyhumanvolunteers
AT parkinmarkc excretionofmephedroneanditsphaseimetabolitesinurineafteracontrolledintranasaladministrationtohealthyhumanvolunteers
AT georgeclaire excretionofmephedroneanditsphaseimetabolitesinurineafteracontrolledintranasaladministrationtohealthyhumanvolunteers
AT kicmanandrewt excretionofmephedroneanditsphaseimetabolitesinurineafteracontrolledintranasaladministrationtohealthyhumanvolunteers
AT darganpauli excretionofmephedroneanditsphaseimetabolitesinurineafteracontrolledintranasaladministrationtohealthyhumanvolunteers
AT abbatevincenzo excretionofmephedroneanditsphaseimetabolitesinurineafteracontrolledintranasaladministrationtohealthyhumanvolunteers